| |
| |
| |
| |
| |
Clinical Update:
OneCellDx, Genetics Institute of America Partner to Launch OncoPredikt HRD Assay
| |
| |
OneCellDx and Genetics Institute of America announced that they have signed a memorandum of understanding for a diagnostics commercialization agreement for the OneCellDx OncoPredikt HRD Assay. Genetics Institute of America will create a laboratory developed test (LDT) based on OneCellDx’s proprietary AI Enabled Algorithm and assay. The OncoPredikt assay identifies Homologous Recombination Deficiency (HRD) in cancer patients with quicker turnaround times and lower costs.
Current HRD prediction tests are expensive, time-consuming, require multi-technique processes, and often have sample QC rejection due to low DNA quantity. OneCellDx has developed a proprietary AI-enabled tool to predict key genomic signatures. Genetics Institute of America will run a validation study in its CAP Accredited, CLIA certified facility and launch the laboratory developed test upon successful completion and acceptance of the study.
To see the whole press release, visit the official announcement on BusinessWire.
Also featured on GenomeWeb!
| |
| |
| |
Enroll your Practice in GH-101! | |
Genetics Institute of America is actively recruiting practices to join our study, GH-101! The objective of this study is to take an integrative approach to the fields of pharmacogenomics, cancer genomics, mRNA microarrays and nutrigenomics by identifying DNA and RNA variants in persons with chronic disease. We are looking for Physicians and Physician Groups that currently treat patients with a chronic disease including: cancer, cardiac conditions, diabetes, kidney disease, PTSD. Getting your practice involved is easy and not only gets patients the individualized health information they need but allows your practice to be on the cutting edge of genetic research. Click "Enroll Now" for more information about this study and enrolling your practice.
| |
| |
| |
| |
Have you Seen This?:
Feasibility of Genetic Testing Implementation | The use of germline genetic testing is rapidly changing cancer care and treatment. New therapy options that are dependent on patients’ germline variants have increased quality of life and survival rates. | | It's All in the Genes:
Genetic Testing in Prostate Cancer Active Surveillance | With one million cases reported every year, prostate cancer (PCa) is becoming one of the world’s most common cancers diagnosed in men. The mortality rate is still high with over 375,000 men dying of PCa in 2020. | | Changing Corporate Culture:
Bringing JOY Every Day
| Genetics Institute of America believes that it is our responsibility to care for the community we are a part of, and that corporate culture can do more to play a greater role in community solutions. | | | |
| |
| |
Thank you for the trust and confidence you have placed in our team here at the Genetics Institute of America. This monthly newsletter is our primary method of communicating to you important information about our testing and assays, general information about the Genetics Institute, as well as information impacting patient care and safety. If you would like to have another person in your practice receive these updates, please forward this to them so that they can subscribe.
 Ana Perez-Miranda, PhD, MDxT (AAB), MB (ASCP) Laboratory Manager and Molecular Diagnostics Supervisor Genetics Institute of America | | | |
| |
| |
| |
| |
GIA Lab News is an educational service of Genetics Institute of America.
Genetics Institute of America is a national laboratory dedicated to heightening the awareness of early intervention and genetic screening to promote the longevity and quality of life outcomes. Our determination and research allow us to provide next generation DNA sequencing to deliver customized testing for identified genetic related cancers and other diseases. | |
| |
| |
4733 W. Atlantic Ave, Suite C16 Delray Beach, FL 33445 Phone: (833) 4GENLAB or (833) 443-6522 HIPAA Fax: (561) 354-5369
| |
You are receiving this email because you opted into receiving communications from Genetics Institute of America online or verbally on the phone, and/or maintain a professional relationship with our laboratory. From time to time, we’ll send newsletters, blog articles, and other educational clinical updates to our subscribers. We hope you find them useful. If not, you can unsubscribe from our list here.
Who do you know that needs to know? Forward this email Did someone forward this to you? Subscribe
Want to change how you receive these emails?
You can Unsubscribe or Update your preferences.
© 2022 Genetics Institute of America. All Rights Reserved.
| |
| |
